BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
BLFS$38.61+3.5%Stored close · as of Oct 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
Checking your notes…
| (In thousands, except share data) | Series APreferredStockShares | Series APreferredStockAmount | CommonStockShares | CommonStockAmount | AdditionalPaid-inCapital | AccumulatedOtherComprehensiveLoss | AccumulatedDeficit | TotalShareholders’Equity |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2021 | — | $— | 41,817,503 | $42 | $585,397 | $(282) | $(107,110) | $478,047 |
| Stock issued as consideration for SciSafe earnout | — | — | 64,130 | — | 817 | — | — | 817 |
| Fees incurred for registration filings | — | — | — | — | (131) | — | — | (131) |
| Stock-based compensation | — | — | — | — | 25,334 | — | — | 25,334 |
| Stock option exercises | — | — | 161,646 | — | 323 | — | — | 323 |
| Stock issued – on vested RSAs | — | — | 788,952 | 1 | (1) | — | — | — |
| Other comprehensive loss | — | — | — | — | — | (397) | — | (397) |
| Net loss | — | — | — | — | — | — | (139,805) | (139,805) |
| Balance, December 31, 2022 | — | — | 42,832,231 | 43 | 611,739 | (679) | (246,915) | 364,188 |
| Stock issued as consideration for SciSafe earnout | — | — | 116,973 | — | 2,263 | — | — | 2,263 |
| Fees incurred for registration filings | — | — | — | — | (132) | — | — | (132) |
| Stock-based compensation | — | — | — | — | 33,245 | — | — | 33,245 |
| Stock option exercises | — | — | 239,043 | — | 507 | — | — | 507 |
| Stock issued – on vested RSA units | — | — | 1,267,837 | 1 | (1) | — | — | — |
| Settlement of Global Cooling escrow | — | — | (216,024) | — | (5,115) | — | — | (5,115) |
| Common stock shares issued | — | — | 927,165 | 1 | 10,374 | — | — | 10,375 |
| Other comprehensive income | — | — | — | — | — | 334 | — | 334 |
| Net loss | — | — | — | — | — | — | (68,002) | (68,002) |
| Balance, December 31, 2023 | — | — | 45,167,225 | 45 | 652,880 | (345) | (314,917) | 337,663 |
| Stock-based compensation | — | — | — | — | 30,923 | — | — | 30,923 |
| Stock option exercises | — | — | 90,250 | — | 202 | — | — | 202 |
| Stock issued – on vested RSA units | — | — | 1,649,290 | 2 | (66) | — | — | (64) |
| Other comprehensive (loss) income | — | — | — | — | — | 369 | — | 369 |
| Net loss | — | — | — | — | — | — | (20,184) | (20,184) |
| Balance, December 31, 2024 | — | $— | 46,906,765 | $47 | $683,939 | $24 | $(335,101) | $348,909 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.